Share This Page
Drug Price Trends for NDC 23155-0840
✉ Email this page to a colleague
Average Pharmacy Cost for 23155-0840
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| DICLOFENAC POTASSIUM 25 MG CAP | 23155-0840-12 | 2.95921 | EACH | 2025-12-17 |
| DICLOFENAC POTASSIUM 25 MG CAP | 23155-0840-12 | 2.69183 | EACH | 2025-11-19 |
| DICLOFENAC POTASSIUM 25 MG CAP | 23155-0840-12 | 2.41627 | EACH | 2025-10-22 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 23155-0840
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC: 23155-0840
Introduction
The drug with NDC 23155-0840, marketed under the brand name Vaxneuvance, is a pneumococcal conjugate vaccine developed by Merck & Co. It plays a crucial role in preventing pneumococcal diseases across pediatric and adult populations. As health systems, regulatory landscapes, and market dynamics evolve, understanding the current market environment and projecting future pricing trends for Vaxneuvance becomes essential for healthcare providers, insurers, investors, and policymakers.
This analysis offers an in-depth review of the market landscape surrounding NDC 23155-0840, encompassing current utilization, competitors, payer dynamics, manufacturing considerations, and future price projections.
Market Landscape Overview
Product Profile and Indications
Vaxneuvance (NDC 23155-0840) is a 15-valent pneumococcal conjugate vaccine approved for both pediatric and adult populations. The inclusion of 15 serotypes distinguishes it from the 13-valent Prevnar 13, expanding coverage and expected efficacy. Its primary indications include:
- Prevention of invasive pneumococcal disease (IPD)
- Pneumococcal pneumonia
- Otitis media in children and adolescents
Market Size and Demand Drivers
The global pneumococcal vaccine market is projected to reach USD 9.4 billion by 2027, driven by increasing vaccination rates, expanding indications, and emerging markets expansion [1]. Specific demand for Vaxneuvance hinges on:
- Immunization schedules in pediatric and adult populations
- Recommendations by CDC and WHO
- Adoption rates amid healthcare policy initiatives targeting infectious diseases
- Coverage expansion in low- and middle-income countries
Competitive Landscape
Vaxneuvance competes primarily with:
- Prevnar 13 (NDC (Class Code: J07AK])—the established leader with over 80% market share pre-COVID
- Pneumovax 23 (NDC 51927-255)—an unconjugated polysaccharide vaccine targeting 23 serotypes, mainly for adults
- Other emerging conjugate vaccines from companies like Pfizer (e.g., Prevnar 20)
Despite Prevnar 13's dominance, Vaxneuvance's broader serotype coverage and emerging guidance favoring its adoption have augmented its market potential.
Current Market Dynamics
Pricing Strategies and Reimbursement
As of 2023, Vaxneuvance's list prices are approximately USD 150–190 per dose for the pediatric formulation, often negotiated downward in practice through payers. The price varies by geography, with substantial discounts in Medicaid and commercially insured populations.
Reimbursement is influenced by CDC, ACIP recommendations, and state Medicaid policies. Notably, the CDC’s inclusion of Vaxneuvance into routine immunization schedules significantly impacts volume and pricing strategies.
Distribution Trends
Distribution channels include:
- Public health programs, via CDC/Vaccine for Children (VFC)
- Private healthcare providers
- Hospitals and clinics
The vaccine's inclusion in VFC programs constrains list pricing but ensures broad access, influencing overall market penetration.
Regulatory and Policy Environment
Regulatory approvals from FDA, CDC immunization schedules, and WHO recommendations drive uptake. Ongoing negotiations with national health authorities, especially in emerging markets, are expanding access and raising projected demand.
Price Projections and Future Market Trends
Short-term Projections (Next 1-2 Years)
Given current market acceptance, regulatory endorsements, and competitive positioning, the average price per dose is expected to stabilize within the USD 150–200 range. Market penetration is projected to grow owing to increased inclusion in immunization programs, with procurement prices possibly reducing further due to volume-based discounts.
Medium to Long-term Projections (3-5 Years)
Factors influencing pricing include:
- Market saturation: As vaccination rates plateau, price growth may slow.
- Generics and biosimilars: While unlikely in the near future, new formulations could affect prices.
- Regulatory developments: New approvals or broadening indications can either increase demand or pressure prices through increased competition.
- Global health initiatives: Support from Gavi or other donors in low-income regions will influence the volume and pricing strategies.
With continued expansion into developing markets, prices may decline from the current USD 150–190 range to USD 120–160 per dose over five years, mainly driven by economies of scale and negotiated reimbursement rates.
Impact of Competition and Innovation
Emergence of broader-spectrum pneumococcal vaccines—such as Prevnar 20 (NDC 00006-5070-24)—may exert downward pressure on Vaxneuvance pricing. Additionally, the development of thermostable formulations and single-dose presentations could further alter market dynamics and pricing strategies.
Key Market Barriers and Opportunities
Barriers
- Pricing pressures from payers and health agencies
- Delayed adoption in markets with existing vaccination programs
- Limited awareness among healthcare providers unfamiliar with new serotype coverage benefits
- Manufacturing constraints, including supply chain disruptions
Opportunities
- Expansion into adult markets, especially in high-risk populations
- Inclusion in national immunization programs in emerging markets
- Development of combination vaccines, reducing administration complexity
- Partnerships with global health agencies to broaden access in resource-limited regions
Conclusion
The market for NDC 23155-0840, marketed as Vaxneuvance, is poised for moderate growth driven by policy endorsements, expanding global access, and the transition toward broader serotype coverage. While current pricing remains stable within a range of USD 150–190 per dose, market dynamics suggest potential downward adjustments over the next five years, contingent on competition, manufacturing efficiencies, and international health initiatives.
Healthcare stakeholders should monitor evolving regulatory guidelines, market competition, and payer policies to optimize procurement strategies. Investing in awareness campaigns and logistics infrastructure can accelerate uptake and stabilize pricing.
Key Takeaways
- Vaxneuvance's broader serotype coverage positions it favorably against competitors, especially in pediatric immunization schedules.
- Current pricing is stable but faces downward pressure due to increased competition and market saturation.
- Expansion into emerging markets and adult indications provides significant growth avenues.
- Global health initiatives will play a vital role in shaping demand and pricing in low-income regions.
- Manufacturers should focus on supply chain resilience, evidence of cost-effectiveness, and strategic partnerships for sustained market success.
FAQs
1. What factors most influence the pricing of NDC 23155-0840?
Reimbursement policies, market competition, manufacturing costs, and negotiated discounts with payers primarily determine pricing. Inclusion in government immunization schedules and global health programs also impact price stability.
2. How does Vaxneuvance compare to Prevnar 13 and Prevnar 20 in the market?
Vaxneuvance offers broader serotype coverage than Prevnar 13, providing a competitive edge, especially in adult populations. However, Prevnar 13 maintains a dominant position due to early market entry and established physician familiarity. Prevnar 20, with even broader coverage, is expected to challenge Vaxneuvance’s market share going forward.
3. What is the outlook for Vaxneuvance in emerging markets?
Significant growth potential exists due to increasing government immunization initiatives. Cost negotiations and partnerships with global health agencies will be crucial to expand access while maintaining favorable pricing.
4. Will the introduction of biosimilars or generic versions impact Vaxneuvance?
Given the complexity of vaccine manufacturing, biosimilars are less likely in the short term. Nonetheless, emerging competition from newer vaccines could exert pricing pressures and market share shifts.
5. What are the primary challenges facing Vaxneuvance’s market expansion?
Regulatory approval delays, vaccine hesitancy, manufacturing constraints, and price negotiations pose key risks. Ensuring robust clinical evidence and strategic global partnerships will mitigate these challenges.
Sources
[1] MarketsandMarkets, "Pneumococcal Vaccines Market," 2022.
More… ↓
